

# NF- $\kappa$ B at the Crossroads of Normal Mammary Gland Biology and the Pathogenesis and Prevention of *BRCA1*-Mutated Breast Cancer

Andrea Sau, Miguel A. Cabrita, and M.A. Christine Pratt



## Abstract

Recent studies have shown that progesterone receptor (PR)-expressing cells respond to progesterone in part through the induction of the receptor activator of NF- $\kappa$ B ligand (RANKL), which acts in a paracrine manner to induce expansion of a RANK-expressing luminal progenitor cell population. The RANK<sup>+</sup> population in human breast tissue from carriers of *BRCA1* mutations (*BRCA1*<sup>mut/+</sup>) as well as the luminal progenitor population in *Brcal*-deficient mouse mammary glands is abnormally amplified. Remarkably, mouse *Brcal*<sup>+/-</sup> and human *BRCA1*<sup>mut/+</sup> progenitor cells are able to form colonies *in vitro* in the absence of progesterone, demonstrating a hormone-independent proliferative capacity. Our research has demonstrated that proliferation in

*BRCA1*-deficient cells results in a DNA damage response (DDR) that activates a persistent NF- $\kappa$ B signal, which supplants progesterone/RANKL signaling for an extended time period. Thus, the transcriptional targets normally activated by RANKL that promote a proliferative response in luminal progenitors can contribute to the susceptibility of mammary epithelial cells to *BRCA1*-mutated breast cancers as a consequence of DDR-induced NF- $\kappa$ B. Together, these latest findings mark substantial progress in uncovering the mechanisms driving high rates of breast tumorigenesis in *BRCA1* mutation carriers and ultimately reveal possibilities for non-surgical prevention strategies. *Cancer Prev Res*; 11(2); 69–80. ©2017 AACR.

## The Mammary Gland Contains Stem and Progenitor Cells that Are Cells of Origin for Breast Cancer Subtypes

In 1998, Kordon and Smith showed that a single cell was able to regenerate a ductal lobular outgrowth with complete luminal and myoepithelial cells (1). FACS based on cell surface receptor immunoreactivity is used to enrich stem/progenitor populations within the mammary gland. Primitive mammary stem cells have been functionally defined in transplantation assays as able to regenerate an entire mammary gland in mice. Transit amplification of progenitors results in subpopulations that include luminal progenitor cells (LP) and basal (myoepithelial) progenitors (2). Primitive luminal progenitor cells are thought to give rise to hormone receptor-positive and negative ductal progenitors and ultimately mature ductal cells. Evidence from lineage-tracing studies suggests that the hormone receptor-negative alveolar lineage may derive from either

a common luminal progenitor or from the basal progenitor pool (reviewed in refs. 2, 3).

On the basis of their gene expression profile, human breast cancers have been categorized into five molecular subtypes: luminal A, luminal B, receptor tyrosine protein kinase *erbB-2* (*ERBB2*) positive, basal-like, and normal-like (4). Although the mammary stem cell genomic signature is most aligned with the normal-like subtype, the luminal progenitor signature more closely resembles the basal-like subtype (5). Subpopulations of luminal progenitors are also proposed to be the target of transformation in luminal A, luminal B, and the *ERBB2*-positive breast cancers (6). Approximately 15% of all breast cancers belong to the basal-like, and more than 90% of *BRCA1*-associated breast cancers belong to this subtype (7).

## Breast Cancer-Associated Gene 1

The *BRCA1* gene was originally mapped in 1990 and cloned in 1994 (8). Mutations in one copy of *BRCA1* gene in the germline lead to the hereditary breast and ovarian cancer syndrome, which is characterized by early-onset cancers and lifetime risks of up to 80% by the age of 70. The *BRCA1* protein plays an important role in maintaining global genomic stability. Single or double DNA strand breaks (SSB or DSB) can occur during normal cellular replication or during exposure to

University of Ottawa, Ottawa, Ontario, Canada.

**Corresponding Author:** M.A. Christine Pratt, Department of Cellular and Molecular Medicine, University of Ottawa, 451 Smyth Road, Ottawa, Ontario K1H 8M5, Canada. Phone: 613-562-5800, ext. 8366; Fax: 613-562-5636; E-mail: cpratt@uottawa.ca

**doi:** 10.1158/1940-6207.CAPR-17-0225

©2017 American Association for Cancer Research.

genotoxic compounds. During replication in S-phase, the genome is particularly susceptible to SSBs that are converted into DSBs. In S-phase, BRCA1 has a role in the high fidelity process of homology-directed DNA repair where it acts as a scaffold protein to assemble a cohort of other DNA repair proteins, including BRCA2, Rad50, and Rad51, to the DSB (9). In the presence of a deleterious mutation in carriers coupled to loss of the normal allele of *BRCA1*, HR is dysfunctional, and DSBs can result in chromosome rearrangements and genomic instability leading to cellular transformation.

More recently, BRCA1 has also been found to have a critical role in the protection of stalled replication forks in an HR-independent manner (10). Replication fork progression is frequently impaired as a consequence of DNA breaks caused by exogenous (such as UV) or endogenous (such as reactive oxygen species) factors or nucleotide depletion. If left unprotected, the meiotic recombination 11 protein (MRE-11) can recognize and degrade stalled replication forks, inducing DNA damage and chromosome instability. BRCA1, together with the Fanconi anemia group D2 protein (FANCD2), BRCA2, and Rad51 can protect stalled forks to prevent nucleotide degradation during replication stress (10). Thus BRCA1 has a critical role in maintaining global genomic stability during normal cell replication and under stressed conditions.

BRCA1 also plays a role in the differentiation of the mammary glands through gene regulation at both the transcriptional and epigenetic levels (11) in response to ovarian hormones (12). Gene expression profiling showed that depletion of BRCA1 upregulates the genes involved in proliferation but downregulates those associated with differentiation (13). Indeed, an important target of BRCA1 is the estrogen receptor (ER) gene, which is positively regulated by BRCA1 through direct DNA binding (14).

### Progesterone Regulates Progenitor Cell Proliferation through NF- $\kappa$ B

Mammary stem and progenitor cells are highly responsive to steroid hormones. Progesterone targets progesterone receptor (PR)-positive mammary epithelial cells to induce proliferation in a cyclin D1-dependent manner (15). In addition, progesterone induces the synthesis and release of the receptor activator for NF- $\kappa$ B ligand (RANKL). Paracrine RANKL, released from PR<sup>+</sup> luminal cells, induces the expansion of the RANK-expressing progenitor cell compartment in the mouse mammary gland. RANKL functions by binding to its receptor RANK, expressed on PR<sup>-</sup> stem and progenitor cells (15–17), thereby activating the transcription factor, NF- $\kappa$ B. RANK signaling promotes the transcription of numerous genes involved in proliferation, including cyclin D1, resulting in expansion of the mammary gland and ductal side branching during mammary gland development (18, 19).

NF- $\kappa$ B not only regulates the transcription of genes involved in proliferation, but also many genes controlling apoptosis/survival and the secondary immune response and plays a critical role in cancer biology (20). Extracellular signal-mediated induction of NF- $\kappa$ B occurs through the TNF $\alpha$  family of receptors and ligands that include RANK and RANKL. Activation of the RANK receptor can activate both types of NF- $\kappa$ B signaling called the canonical pathway and the alternative pathway (21). The canonical NF- $\kappa$ B pathway typically consists of a p65/RelA;p50 heterodimer whose nuclear translocation is stimulated by the inhibitor of  $\kappa$ B kinase (IKK $\alpha$ /IKK $\beta$ /NEMO) complex, which results in the degradation of the cytoplasmic inhibitor, I $\kappa$ B $\alpha$ . This releases p65/p50, which then moves into the nucleus. The proteins p52 and RelB constitute the alternative NF- $\kappa$ B pathway, which is dependent on IKK $\alpha$ -mediated phosphorylation for its activation and nuclear localization (reviewed in ref. 22). Interestingly, NEMO and IKK $\alpha$  can also form a functional IKK complex able to activate the alternative NF- $\kappa$ B pathway (23). Once in the nucleus, NF- $\kappa$ B dimers bind  $\kappa$ B enhancer sequences in target genes and regulate transcription through the recruitment of coactivators or corepressors.

### NF- $\kappa$ B Drives Normal Mammary Cell Proliferation and Contributes to Tumorigenesis

NF- $\kappa$ B is an integral player in the normal postnatal morphogenesis of the mammary gland. NF- $\kappa$ B activity is high during pregnancy, decreases during lactation, and increases again during involution. This pattern demonstrates the contrasting regulatory roles of NF- $\kappa$ B during the pregnancy (proliferative) and involution (apoptotic) phases of the mammary gland (24, 25). Mice deleted for *Rank* or *Rankl* had normal mammary gland development after birth; however, mammary glands showed increased apoptosis and failed to form lobuloalveolar structures during pregnancy (26). Transgenic expression of mammary gland *Rank* in mice prevents development of a functional mammary gland, showing increased proliferation during pregnancy, impaired differentiation, and decreased expression of the milk protein,  $\beta$ -casein. Moreover, constitutive overexpression of RANK resulted in the development of hyperplasias at advanced age (27). Importantly, mice lacking the catalytic domain of IKK $\alpha$  show a lactation defect similar to *Rank*-null mice (18), suggesting that the alternative NF- $\kappa$ B pathway plays a key role in the response to RANKL in the mammary gland.

Altogether, these data show that RANK/NF- $\kappa$ B signaling is a critical regulator of mammary epithelial cells in the luteal phase and during pregnancy, whereas dysregulation is associated with failure of cell differentiation. As a consequence of its important participation in cyclin D1 and RANKL regulation, progesterone is now recognized as

having a central role in the pathophysiology of mammary neoplasia (28).

Several studies have shown that NF- $\kappa$ B is activated in breast cancers, and this activation is increased with hormone independence. NF- $\kappa$ B was found constitutively active in the nucleus of human breast cancer cells, while no detectable levels were found in normal cells (29). We and others have shown that the canonical NF- $\kappa$ B pathway appears to be most active in the ER<sup>+</sup> and HER2<sup>+</sup> breast cancers (30, 31). Moreover, we have demonstrated that transgenic inhibition of NF- $\kappa$ B by the stable "superrepressor" inhibitor of  $\kappa$ B (IkB $\alpha$ <sup>SR</sup>) increases the latency and decreases the incidence of carcinogen-induced mammary adenomas and carcinomas (32). NF- $\kappa$ B can also regulate epithelial-to-mesenchymal transition (EMT), a key process in breast cancer progression (33). More recently, it was demonstrated that both the canonical and alternative NF- $\kappa$ B pathways are required for the self-renewal and proliferation of tumor-initiating cells through the stimulation of genes involved in EMT (34). A direct link between alternative NF- $\kappa$ B activation and breast cancer initiation was established using a mouse mammary p100/p52 transgenic model wherein mice showed a delay in mammary gland development and reduction in ductal branching during pregnancy. Instead, these mice had thickening of primary ducts, loss of epithelial cell organization, and hyperplasia (35). RelB has also been found to be increased in ER $\alpha$ <sup>-</sup> breast cancer. Indeed, RelB is necessary to maintain the mesenchymal phenotype of ER $\alpha$ <sup>-</sup> breast cancer through the direct transcriptional activation of *BCL2* (36). In an analysis of microarray data from 249 human breast tumors, we found that p100/p52 and RelB gene expression is predominantly expressed in TNBC (32). Consistent with this, another study showed that p100/p52 and RelB expression is higher in *BRCA1*-mutated tumors compared with other subtypes (37). The association of NF- $\kappa$ B with the development of basal-like tumors is also supported by identification of EMT-associated gene targets. NF- $\kappa$ B induces the mesenchymal-specific gene vimentin and suppresses the expression of epithelial-specific gene E-cadherin by inducing the expression of Snail (38) and the transcription factors ZEB1 and ZEB2 (39) and Slug (40, 41). Moreover, NF- $\kappa$ B has been shown to be critical for maintenance of the mesenchymal phenotype as blocking of NF- $\kappa$ B results in a partial MET (39). Transcription of the *ESR1* gene is also negatively regulated by RelB (42), which would prevent differentiation into hormone-sensing cells.

### NF- $\kappa$ B Is Activated by DNA Damage

In addition to its activation by ligands through receptor-mediated signaling, NF- $\kappa$ B is also induced in response to genotoxic stresses. Following irradiation or chemotherapeutic drugs that cause double-strand DNA breaks, the ATM kinase is activated and phosphorylates H2AX, leading to the recruitment of several other proteins involved in

DNA damage response (DDR; 43). Early evidence demonstrated that ATM activation in response to genotoxic stimuli was also instrumental in the induction of NF- $\kappa$ B (44). Subsequent studies revealed that activation of ATM in response to DNA double-strand breaks was necessary for the phosphorylation of NEMO, which resulted in IKK activation resulting in an atypical mechanism of inducing NF- $\kappa$ B activity (45). Although cells heterozygous for *BRCA1* are competent for most functions, including HR, they demonstrate significant genomic instability (46) and are hypersensitive to genotoxic stress (47). Consistent with this, NF- $\kappa$ B can also be induced by replication stress (45). Indeed, *BRCA1*<sup>+/-</sup> cells are susceptible to replication fork stalling and collapse (10). Thus, replication stress, coupled to stalled fork instability is likely a critical factor precipitating DNA damage in *BRCA1* mutation carriers.

### Abnormal Progenitor Cells in *BRCA1* Mutation Carriers: Basal Breast Cancer Originates in the Luminal Progenitor Population

As discussed, *BRCA1* expression is required for normal differentiation of ER<sup>-</sup> stem/progenitor cells to luminal cells by modulating critical pathways determining cell fate. Consequently, knockdown of *BRCA1* in primary breast epithelial cells leads to increased expression of the stem/progenitor cell marker aldehyde dehydrogenase 1 (ALDH1) and a decrease in cells expressing luminal epithelial markers and the ER $\alpha$ . Although normal control mammary lobules are marked with ER<sup>+</sup>/ALDH<sup>-</sup> cells, remarkably, sections of breast tissue from women with germline *BRCA1* mutations contain entire lobules displaying loss of heterozygosity that express ALDH1 but not the ER (48).

Examination of the mammary progenitor cell populations from *BRCA1* mutation carriers, including basal stem/progenitor, luminal progenitor, and mature luminal cells, showed that these glands contain an expanded luminal progenitor population. Intriguingly, unlike normal progenitor cells, the *BRCA1*<sup>mut/+</sup> luminal population was able to proliferate and form colonies *in vitro* in the absence of several media supplements, including progesterone (49). Thus, *BRCA1*<sup>mut/+</sup> cells must possess an intrinsic mechanism that conveys the ability to grow for extended periods without hormonal stimulation. The gene expression profiles of ostensibly normal luminal progenitor cells from breast tissue heterozygous for a *BRCA1* mutation and the basal breast cancer signature are highly similar suggesting for the first time that basal breast cancers may arise from an (early) luminal progenitor rather than the mammary stem/bipotent subpopulation. Indeed, specific deletion of *Brca1* in mouse mammary epithelial luminal progenitors using a luminal keratin promoter to drive expression of the cre-recombinase in *Tp53*<sup>-/+</sup> mice results in

Sau et al.


tumors that phenocopy human *BRCA1* breast cancers and non-*BRCA1* basal breast cancers. In contrast, *Brca1* deficiency mediated by a basal keratin promoter driving cre results in tumors that have basal breast cancer gene expression profiles but are not histologically similar to *BRCA1*-deficient or the majority of sporadic basal-like human breast tumors (50). This finding was also supported by a study by Bai and colleagues (2013) showing that *BRCA1* deficiency resulted in a luminal to basal transformation of luminal progenitors resulting in basal mammary cancers in mice (51).

Further studies (52) reported that the transcriptional repressor Slug that participates in EMT is abnormally expressed in *BRCA1*<sup>mut/+</sup> mammary tissue. Slug is required for promoting a basal-like phenotype in progenitor and cancer cells, making it a key effector of the gene expression program that may ultimately contribute to the transformed basaloid phenotype.

### The Progesterone/RANKL Axis and Breast Cancer Risk in *BRCA1*-Deficient Mammary Luminal Progenitors

The PR antagonist, RU486 (mifepristone), has been shown to prevent mammary cancer in *Brca1/Trp53*-deficient mice (53). As noted above, breast cancers arising in this population typically belong to the ER/PR and HER2<sup>-</sup> basal subtype. Recent work by Nolan and colleagues (54) has shown that RANK<sup>+</sup> cells from *BRCA1*<sup>mut/+</sup> mammary glands are highly proliferative and have a molecular signature resembling basal breast cancer. Women treated with the RANKL inhibitor denosumab prior to biopsy showed reduced Ki67<sup>+</sup> cells. They also demonstrated that mammary outgrowths from transplanted *Brca1*<sup>-/-</sup>;*Trp53*<sup>+/-</sup> mammary cells developed fewer tumors with longer latency than controls when mice were treated with denosumab. A contemporaneous study (55) showed similar results in *Brca1*<sup>-/-</sup> mice. Interestingly, the enriched luminal progenitor population from *BRCA1*<sup>mut/+</sup> carriers expressed a higher level of RANK<sup>+</sup> cells compared with normal controls, and benign hyperplastic mammary tissue from the *Brca1*<sup>-/-</sup>;*Trp53*<sup>+/-</sup> mice also expressed high levels of RANK. Together, these two studies support the potential for RANKL inhibition as a viable new option for preventative treatment for women with *BRCA1* mutations.

Increased RANKL production by *BRCA1*-deficient PR<sup>+</sup> epithelial cells could coordinately increase proliferation *in vivo* to promote an expanded luminal progenitor population. However, increased RANKL in *BRCA1* deficiency has not been reported nor does this account for the ability of these cells to continue to proliferate and form colonies *in vitro* in the absence of progesterone. As discussed above, signals transduced by the DDR can activate NF-κB. Given that *BRCA1* is a critical DNA repair protein and is involved in protection of the stalled replication fork, we investigated whether or not *BRCA1*-deficient cells demonstrate abnor-



**Figure 1.**

*BRCA1* deficiency leads to enhanced proliferation of RANK<sup>+</sup> cells: diagram showing the sequence of events following progesterone (P4)-induced RANKL-mediated stimulation of RANK<sup>+</sup> luminal progenitor cells. *BRCA1* deficiency increases replication fork stalling and reduces fork protection leading to a DDR to initiate repair. The DDR simultaneously activates NF-κB through an ATM/NEMO-dependent pathway, thus establishing a proliferation-*DDR*-NF-κB feed-forward cycle.


mal activation of NF-κB signaling (56). We assessed the activation of this pathway in mammary progenitors and found that p65/RelA is transiently activated by phosphorylation at ser536 following *BRCA1* knockdown while p52/RelB is persistently activated in a subset of luminal progenitors with either homozygous or heterozygous deletion of *BRCA1*. Numerous lobular structures in sections from *BRCA1* mutation carriers showed high levels of p52 compared with normal mammary tissue. Knockdown of both p100/p52 and the inhibitor of kappaB kinase, IKKα, revealed that factor-independent *in vitro* proliferation required these NF-κB pathway constituents. We found that the DDR protein, ataxia telangiectasia-mutated (ATM), was phosphorylated accompanied by P-H2AX foci in human cell lines expressing si*BRCA1* and mouse mammary progenitors deficient in *Brca1*. Activated ATM is required for NF-κB activation by the DDR (44, 57). The involvement of the DDR was further substantiated by demonstrating that hormone-independent luminal progenitor colony formation required ATM (56). In addition progesterone-stimulated proliferation resulted in a marked enhancement of DNA damage foci in *Brca1*<sup>-/-</sup> mouse mammary glands in our study as confirmed in subsequent studies (54, 55).

**Figure 2.**

Proposed effects of *BRCA1* deficiency on relative subsets of luminal progenitor cells in premenopausal and postmenopausal mammary tissue.

**A**, In normal premenopausal women, E2 levels rise in the follicular phase and activate a subset of ER<sup>+</sup> cells to divide. *BRCA1* deficiency would increase the likelihood of a DDR in the ER<sup>+</sup> population and subsequent activation of NF- $\kappa$ B. However, ER<sup>+</sup> cells may have lower proliferative capacity than RANK<sup>+</sup> cells in premenopausal glands and represent a smaller percentage. In the luteal phase, progesterone (P4) stimulation of paracrine RANKL results in proliferation of RANK<sup>+</sup> cells, which leads to a DDR in *BRCA1*-deficient cells and enhanced activation of NF- $\kappa$ B (denoted in bold type), followed by further proliferation. This leads to an expansion of the RANK<sup>+</sup> population in the *BRCA1*<sup>mut/+</sup> gland, which persists beyond the cycle into the next as evidenced by the increased RANK<sup>+</sup>:ER<sup>+</sup> ratio in the follicular phase.

**B**, After menopause, the proportion of ER<sup>+</sup> cells increases in normal (not shown) and *BRCA1*-deficient mammary tissue, and proliferation is induced by E2, which may be higher than normal as a consequence of loss of *BRCA1* repression of the aromatase gene (see text and Fig. 3 for details).




Treatment of MMTV-cre;*Brca1*<sup>fl/fl</sup> mice with a water soluble derivative of the natural product of the feverfew weed, parthenolide, called DMAPT (dimethyl-amino parthenolide), prevented the recovery of *Brca1*<sup>-/-</sup> hormone-independent colony-forming cells. DMAPT is an NF- $\kappa$ B inhibitor and a differential inducer of reactive oxygen species in cancer cells, but has little effect on normal cells (58, 59). Importantly, dosing of mice with DMAPT resulted in prolonged inhibition of factor-independent growth lasting over 4–5 estrus cycles. Consistent with both DDR-activated NF- $\kappa$ B and RANKL/RANK signaling *in vivo*, the majority of human *BRCA1*<sup>mut/+</sup> mammary glands showed marked lobular expression of nuclear p52 NF- $\kappa$ B. Thus, the aberrant hormone-independent proliferative capacity of *Brca1*-deficient luminal progenitor cells initially induced by the progesterone/RANKL axis is linked to replication-associated DDR, where proliferation of mammary progenitors is

perpetuated by feed-forward damage-induced, autologous NF- $\kappa$ B signaling (Fig. 1).

A reduced serum level of the endogenous antagonist of RANKL, osteoprotegerin (OPG) has also been proposed as a mechanism underlying abnormal proliferation in the mammary glands of *BRCA1* mutation carriers. In support of OPG levels as a contributing risk factor, serum OPG from a limited number ( $n = 18$ ) of *BRCA1/2* mutation carriers (60) and from the general population ( $n = 78$ ; ref. 61) have been negatively correlated with breast cancer incidence. Low OPG levels have been associated with increased proliferation in primate mammary tissues (62). Both serum and mammary OPG levels were reduced in progesterone-treated animals in the latter study, suggesting that serum levels are representative of mammary tissue levels; however, serum levels in patients do not appear to vary with the menstrual cycle (62) indicating that cyclic

Sau et al.

**Figure 3.**

Proposed model of oncogenic gene regulation by NF-κB in premenopausal and menopausal mammary epithelial cells. **A**, NF-κB induces transcription of *c-myc*, which induces proliferation and also activates the *BRCA1* promoter, which is important to facilitate differentiation by repressing basal genes and attenuating proliferation. In *BRCA1*-deficient cells the DDR-enhanced NF-κB activity (bold) would increase *c-myc* expression; however, mutations in *BRCA1* can render the protein unable to mediate its function in differentiation. **B**, After menopause, ER<sup>+</sup> cells can be induced to proliferate by E2 in part by the induction of cyclin D1. Cyclin D1 is also an NF-κB target gene, and the resulting DDR/NF-κB axis could further enhance this signaling. In addition, *BRCA1* deficiency may increase breast production of E2 as a consequence of increased aromatase expression. See text for details.

variation in progesterone levels in women is insufficient to alter OPG expression. Although it is not clear why OPG levels would be reduced in *BRCA1*<sup>mut/+</sup> patients, the significant inverse association between luteal progesterone level and serum levels of OPG in *BRCA1* carriers may be a function of the previously reported increased progesterone levels in these patients (63). However, complicating the correlation between low OPG levels and higher breast cancer risk is data showing that progesterone levels are lower in those carriers of mutations with a high hazard ratio, which would presumably reduce RANKL production

and as well as mitigate any hormonal effects on OPG (62). Interestingly, a study of a large cohort (>2,000) of breast cancer cases has shown that higher serum concentrations of OPG were associated with increased incidence of ER<sup>-</sup> breast cancers (64), which is the predominate histologic subtype that develops in *BRCA1* mutation carriers. Taken together, the interplay between OPG expression and hormone levels in *BRCA1* mutation carriers is likely to be complex and may be dependent on specific mutations in this gene.

On the basis of hormone levels, the different phases of the menstrual cycle and menopause involve proliferation of different subsets of mammary epithelial cells. During the follicular phase when β-estradiol (E2) levels are increasing, at least a subset of ER<sup>+</sup> cells may undergo proliferation, which would be expected to induce a DDR resulting in activation of NF-κB in *BRCA1*<sup>mut/+</sup> patients (Fig. 2A). Although in the normal gland, the ratio of RANK<sup>+</sup> to RANK<sup>-</sup> luminal progenitor cells is predicted to increase in the luteal phase and be reduced during the follicular phase of the menstrual cycle, this ratio appears to be greater in *BRCA1*<sup>mut/+</sup> mammary glands relative to normal glands in random cycling patients (56) presumably as a consequence of autologous NF-κB activity and prolonged proliferation. In ovariectomized or postmenopausal *BRCA1* mutation carriers, progesterone levels are dramatically lower (Fig. 2B). Low progesterone levels would presumably obviate hormonally stimulated RANKL production by PR<sup>+</sup> mammary epithelial cells and ultimately reduce the transformation of the RANK<sup>+</sup> population. Although this suggests that premenopausal progesterone is a significant risk factor of breast cancer in *BRCA1* mutation carriers, the benefit of oophorectomy is not clear with several studies showing no benefit while others demonstrate significant or marginal benefit (ref. 65 and references therein). Nevertheless, as described above, the progesterone-independent growth of *BRCA1*<sup>mut/+</sup> luminal progenitors *in vitro* indicates the presence of an intrinsic defect in these presumptive breast cancer precursors (49), which might account in part for the variable effectiveness of oophorectomy on risk reduction.

Interestingly, similar to the non-*BRCA1*-mutated breast cancers, postmenopausal *BRCA1* carriers tend to develop more ER<sup>+</sup> breast cancers (66, 67). The proportion of ERα<sup>+</sup> cells increases after menopause such that the majority of epithelial cells in some lobules express the ERα (68). Aromatase is the key enzyme involved in E2 synthesis by conversion of testosterone to E2 and indirectly by conversion of androstenedione to estrone, which is a substrate for 17β-hydroxysteroid dehydrogenase-mediated conversion to E2. Although systemic E2 and progesterone levels dramatically decrease after menopause, levels of E2 in breast tissue have been reported to increase as a consequence of increased activity of aromatase (69) predominantly in adipose cells (70), which increase as a proportion of the

mammary stroma with age. Although low abundance in the premenopausal breast, ER<sup>+</sup> proliferating cells significantly increase with age (71–73). *BRCA1* is an inhibitor of aromatase (*CYP19*) transcription (74, 75) and also interferes with transcriptional activation mediated by the ER $\alpha$  (76). Thus, *BRCA1* deficiency may render at least some mutation carriers more likely to produce increased levels of estradiol in the postmenopausal breast, which would stimulate the ER $\alpha$  in responding cells with a reduced level of *BRCA1*-mediated transcriptional interference.

### NF- $\kappa$ B Target Genes Are Oncogenes Expressed in Basal and Luminal Breast Cancers

Although NF- $\kappa$ B regulates many genes, two key target genes in the mammary gland that relate to both ductal and lobuloalveolar morphogenesis may play different roles in proliferation and tumorigenesis in the pre- and postmenopausal *BRCA1*<sup>mut/+</sup> mammary gland. The *c-MYC* gene is induced by NF- $\kappa$ B (7) and normally plays a role in both proliferation and differentiation as overexpression induces precocious lobuloalveolar development and lactation (77). As depicted in Fig. 3A, *c-MYC* also mediates the induction of the *BRCA1* gene (78), which is critical for normal differentiation of luminal progenitor cells into mature luminal cells. *BRCA1* in turn attenuates the transforming function of *c-MYC* (79) and forms a complex with the *c-MYC* protein that represses genes associated with the basal phenotype (80). Therefore, it is possible that haploid *BRCA1* may be insufficient to mediate differentiation as a response to NF- $\kappa$ B-driven *c-MYC* expression, instead permitting further proliferation without differentiation. Indeed, *c-MYC* is overexpressed in both *BRCA1*-deficient premalignant mammary glands and tumors (81) and is a component of the basal mammary tumor signature (80). It is important to note that deleterious mutations may also alter the ability of *BRCA1* to regulate gene expression necessary for normal differentiation of mammary luminal progenitor cells. NF- $\kappa$ B would contribute directly, simultaneously increasing proliferation and survival signaling within this cell population. Together, these factors contribute in different ways to the accumulation of genomically unstable luminal progenitors, ultimately leading to a high risk of breast cancer.

NF- $\kappa$ B can collaborate with the ER $\alpha$  in the induction of the cyclin D1 gene in the mammary gland (18, 82), which is critical for lobuloalveolar morphogenesis during pregnancy (83). Cyclin D1 also functions to block *BRCA1*-mediated ER $\alpha$  transcriptional repression (84). Interestingly, high expression of cyclin D1 is a feature of the ER<sup>+</sup> luminal breast cancers that develop in DNA repair-deficient *BRCA2* mutation carriers (85, 86). Therefore, by promoting cyclin D1 expression in *BRCA1*-deficient cells, autologous NF- $\kappa$ B activity activated by the DDR in the postmenopausal gland could contribute and

synergize with E2 to promote proliferation in *BRCA1*-deficient ER<sup>+</sup> mammary epithelial cells (Fig. 3B). This activity would be exacerbated by the reduced levels of functional *BRCA1*, defective in the ability to repress ER $\alpha$ -mediated transcription.

Another potential protumorigenic consequence of a DDR-activated NF- $\kappa$ B response in the mammary gland is the induction of the cytokine IL6. NF- $\kappa$ B has been shown to activate the miRNA-processing factor Lin28 to reduce repression of *IL6* promoter by Let-7 (87). IL6 is expressed in breast cancers, and serum levels can be correlated with poor prognosis (88, 89). Importantly, IL6 also participates in a feed-forward inflammatory signaling loop, which promotes further NF- $\kappa$ B and JNK2 activation. JNK2 phosphorylation of heat shock transcription factor-1 (HSF1) facilitates epigenetic change at the *IL6* promoter resulting in transactivation by NF- $\kappa$ B (90). The ensuing IL6 expression further activates NF- $\kappa$ B (87). Exposure of mammary stem cells to IL6 results in expansion of primary progenitor cells as assayed by the formation of secondary mammospheres and resistance to hypoxia (91). Notably, IL6 expression was found exclusively in basal breast cancers in the latter report. On the basis of this information, it is tempting to speculate that *BRCA1*-deficient mammary LPs, by virtue of DDR-activated NF- $\kappa$ B may establish an IL6 feedback loop that contributes to the perpetuation of proliferative signaling.

### Perspective on the Breast as a Target of Transformation in *BRCA1/2* Mutation Carriers and Implications for Prevention

Although *BRCA1* mutation has been associated with pancreatic and colorectal cancers, the level of risk does not approach that of breast or ovarian cancers (92, 93). Deleterious *BRCA1* mutations resulting in a DDR perpetuate NF- $\kappa$ B signaling in RANK<sup>+</sup> mammary luminal progenitor cells, which are programmed to proliferate in response to NF- $\kappa$ B downstream of RANKL. This renders mammary luminal epithelial cells subject to the pathogenic proliferative activation by NF- $\kappa$ B. In contrast, in certain cells in a stimulus-dependent manner, NF- $\kappa$ B can promote cell death (94). Even within the mammary gland, the response to activation of NF- $\kappa$ B in luminal progenitors is the opposite to that of differentiated alveolar cells that undergo cell death during involution in response to the TNF-like weak inducer of cell death (TWEAK)-stimulated NF- $\kappa$ B (95). Thus, by promoting proliferation/DNA synthesis in *BRCA1*-deficient/mutation-prone progenitor cells, NF- $\kappa$ B functions as both a tumor initiator and promoter in the mammary gland.

Significant advances in identifying and characterizing the mammary gland cell hierarchy in the past decade have provided major insight into the origins and subtypes of breast cancers. We have shown that *BRCA1* mutation-associated breast cancers represent a subgroup of

basal breast cancers whose inherent deficiency in DNA repair promotes not only genomic instability but also proliferative signaling that enhances the risk of transformation (56). In premenopausal women, the progesterone/RANKL/RANK axis initiates the proliferation/DNA damage cycle in RANK<sup>+</sup> cells resulting in basal breast cancers. In the postmenopausal breast, E2 produced in the breast parenchyma and stroma becomes the dominant hormone. E2-induced proliferation of ER<sup>+</sup> cells deficient for BRCA1 would also generate a DDR resulting in the activation of NF-κB, which in turn would augment or synergize with E2/ERα-mediated transcription enhancing the possibility for transformation in the ER<sup>+</sup> progenitor population. Collectively, the results described above inform potential new approaches to the management of BRCA1 mutation carriers. Young, premenopausal patients wishing to postpone mastectomy might opt instead for chemoprevention using denosumab to block RANKL stimulation of progenitor proliferation. Alternatively, transient blockade of NF-κB during the luteal phase of the menstrual cycle might be employed to inhibit RANKL signaling as well as the ongoing propagation of NF-κB activity resulting from DNA damage. On the basis of the long-term effects on aberrant LPs in mice (57), DMAPT treatment might only be required at 2- to 3-month intervals. Such a regime would mitigate issues associated with the systemic suppression of NF-κB for extended periods. On the basis of the potential for a proliferation-associated DDR and subsequent NF-κB activation, DMAPT or another NF-κB inhibitor might also be effective as a prevention strategy in the postmenopausal setting. However, a switch from denosumab to a selective ER modifier, such as tamoxifen, may be more appropriate for chemoprevention in postmenopausal individuals, where E2 is likely to have the predominate proliferative influence on ER<sup>+</sup> cells. Going forward, evidence establishing IL6 as a downstream target of NF-κB in the aberrant proliferation in BRCA1<sup>mut/+</sup> glands could support the use of tocilizumab (a humanized anti-IL6 receptor antibody) as an alternative biologic agent (96).

Our finding that the DDR in BRCA1 mutation carriers activates persistent NF-κB signaling may also have implications in high-risk individuals with mutations in other DNA repair genes, including BRCA2 and PALB2 (97), where replication stress-induced DNA damage might extend hormone-initiated proliferation and exacerbate genomic instability in DNA repair-deficient mammary progenitor cells. Germline BRCA2 mutations are associated with an approximate breast cancer risk of 55% by age 70 (98). Lifetime risk associated with PALB2 mutation has been estimated at 35% (99). Both proteins participate in the response to replication stress to facilitate fork recovery, participate in homologous recombination to prevent genomic instability (100). BRCA2 mutation carriers more typically develop ER<sup>+</sup>/luminal B cancers (ref. 101 and refs therein), suggesting that they originate in a different subset

of LPs than those primarily affected by BRCA1 mutations. In the human gland, the FACS-enriched LP population can be further subdivided into RANK<sup>+</sup> and RANK<sup>-</sup> cells where basal breast cancers are thought to arise from the RANK<sup>+</sup>/ER<sup>-</sup> subset of LPs (16). wtBRCA1 alleles are expected to facilitate the maintenance of differentiated luminal cells (102). Importantly, the expression of BRCA1 is reduced in RANK<sup>-</sup> LPs relative to RANK<sup>+</sup> LPs (54). Thus, ER<sup>-</sup>/RANK<sup>+</sup> LPs may differentiate normally in BRCA2 mutation carriers. Cells originating from within the spectrum of Sca1<sup>+</sup>/RANK<sup>-</sup> LPs that contains a subpopulation of ER<sup>+</sup> cells (16) may be the most probable candidates as a target population for transformation resulting in ER<sup>+</sup> luminal cancers in BRCA2 mutation carriers (2).

Although luminal B breast cancers are ER<sup>+</sup>, they are more aggressive than luminal A tumors and are often resistant to endocrine therapies (103). Many studies, including our own (104–106), have demonstrated antagonistic signaling between the ERα and NF-κB. Indeed, basal breast cancers lacking the ERα express higher levels of NF-κB compared with luminal cancers (32, 107). NF-κB activation in conjunction with the pioneering factor, FOXA1, stimulates binding of the ERα to a novel cistrome (108), which was associated with better prognosis in breast tumors. However, several laboratories have reported that estrogen and TNF signaling through NF-κB can synergize in promoting proliferation in breast cancer cells (109, 110). A subset of ERα-regulated genes and genes not normally regulated by estrogen alone that are associated with survival are induced by TNFα or estrogen and combinations thereof in MCF-7 breast cancer cells. Comparison with breast cancer signatures demonstrated that constituents of this gene set positively coregulated by the ERα and NF-κB are significantly enriched in the luminal B signature (111). Furthermore, the inhibitor of κB kinase-α (IKKα) and the ERα directly interact and knockdown of IKKα potently reduces the transcription of proliferation-associated genes including *CCD1* (cyclin D1) and *c-MYC* (112). Thus, NF-κB, induced in response to the DDR in BRCA2-deficient cells, could contribute to tumorigenesis in ERα<sup>+</sup> cells through the cooperative transactivation of key proto-oncogenes and/or survival factors. Given the significant differences between the molecular phenotypes of the breast cancers that develop in BRCA1 and BRCA2 mutation carriers, prudent approaches to prevention for BRCA2<sup>mut/+</sup> patients would include estrogen receptor-targeted agents such as tamoxifen as an inhibitor of the primary stimulus for proliferation of ER<sup>+</sup> LPs. DDR-activated NF-κB might also be considered as an intermittent target to prevent extended proliferation and block cooperative gene transactivation between the ERα and NF-κB or IKKα.

The Fanconi anemia protein PALB2 serves as a link between BRCA1 and BRCA2 during HDR at DNA breaks (113, 114) and is emerging as clinically relevant familial breast cancer gene. BRCA2 interacts with the C-terminus of



PALB2 (115), while association with *BRCA1* occurs in the N-terminal regions of PALB2 (113, 114). Overall about 30% to 40% of *PALB2*-mutated tumors are triple negative, while 60% to 70% are ER<sup>+</sup> (116, 117). Interestingly, a familial *PALB2* mutation that prevents *BRCA1* interaction is associated with ER<sup>+</sup> breast cancers (118). The nature of the mutation in *PALB2* could therefore determine whether the ultimate deficiency in replication fork stabilization or HDR resembles a *BRCA1* or a *BRCA2* mutation phenotype. From the standpoint of hormone-based prevention, a lack of information on the specific breast cancer subtypes that develop across a broader range of *PALB2* mutation carrier families makes rational decisions regarding the targeting the progesterone/RANKL axis versus the ER $\alpha$  for prevention more challenging. However, basing chemoprevention on the breast cancer diagnosis and use of endocrine therapy to treat previous disease in first-degree relatives when available might be a reasonable strategy. It is feasible that breast cancer-associated mutations in *PALB2* would also elicit a DDR resulting in NF- $\kappa$ B activation and affording abnormal proliferative capacity to the affected subpopulation(s) of LPs. NF- $\kappa$ B may then be a viable target in these individuals that ostensibly would be independent of the nature of the mutation.

As with any intervention, neither hormonal nor agents targeting NF- $\kappa$ B signaling pathways are without potential

side effects. Therefore, the estimated risk-to-benefit ratio must be taken into account and that associated with mutations in *PALB2*, for example, is considerably less than that for *BRCA1* or *BRCA2* mutations. Nevertheless, family histories might provide a more individual risk profile that could enter into decision making regarding prophylactic therapy. Although long-term prevention clinical trials are difficult and expensive, the high risk associated with *BRCA1/2* mutations makes this population a strong candidate for chemoprevention and patient compliance. As mastectomy is the only current form of primary prevention, window of opportunity trials in the months before scheduled surgery or core biopsy (the latter as described for preliminary assessments of denosumab; ref. 54) could provide a unique opportunity for assessing intermediate endpoints such as a reduced proliferative index on non-cancerous breast sections. Application of mechanism-based primary prevention strategies in these high-risk populations ultimately has the potential to avoid the often intractable complexities of treating cancer.

#### Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.

Received August 3, 2017; revised October 3, 2017; accepted October 27, 2017; published OnlineFirst November 3, 2017.

#### References

- Kordon EC, Smith GH. An entire functional mammary gland may comprise the progeny from a single cell. *Dev Camb Engl* 1998;125:1921–30.
- Visvader JE, Stingl J. Mammary stem cells and the differentiation hierarchy: current status and perspectives. *Genes Dev* 2014;28:1143–58.
- Arendt LM, Kuperwasser C. Form and function: how estrogen and progesterone regulate the mammary epithelial hierarchy. *J Mammary Gland Biol Neoplasia* 2015;20:9–25.
- Perou CM, Sørlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, et al. Molecular portraits of human breast tumours. *Nature* 2000;406:747–52.
- Shehata M, Teschendorff A, Sharp G, Novcic N, Russell IA, Avril S, et al. Phenotypic and functional characterisation of the luminal cell hierarchy of the mammary gland. *Breast Cancer Res BCR* 2012;14:R134.
- Visvader JE. Keeping abreast of the mammary epithelial hierarchy and breast tumorigenesis. *Genes Dev* 2009;23:2563–77.
- Foulkes WD, Stefansson IM, Chappuis PO, Bégin LR, Goffin JR, Wong N, et al. Germline *BRCA1* mutations and a basal epithelial phenotype in breast cancer. *J Natl Cancer Inst* 2003;95:1482–5.
- King M-C. "The race" to clone *BRCA1*. *Science* 2014;343:1462–5.
- Venkitaraman AR. Cancer suppression by the chromosome custodians, *BRCA1* and *BRCA2*. *Science* 2014;343:1470–5.
- Schlacher K, Wu H, Jasin M. A distinct replication fork protection pathway connects Fanconi anemia tumor suppressors to *RAD51-*BRCA1/2**. *Cancer Cell* 2012;22:106–16.
- Mullan PB, Quinn JE, Harkin DP. The role of *BRCA1* in transcriptional regulation and cell cycle control. *Oncogene* 2006;25:5854–63.
- Xu X, Wagner KU, Larson D, Weaver Z, Li C, Ried T, et al. Conditional mutation of *Brc1* in mammary epithelial cells results in blunted ductal morphogenesis and tumour formation. *Nat Genet* 1999;22:37–43.
- Furuta S, Jiang X, Gu B, Cheng E, Chen P-L, Lee W-H. Depletion of *BRCA1* impairs differentiation but enhances proliferation of mammary epithelial cells. *Proc Natl Acad Sci U S A* 2005;102:9176–81.
- Hosey AM, Gorski JJ, Murray MM, Quinn JE, Chung WY, Stewart GE, et al. Molecular basis for estrogen receptor alpha deficiency in *BRCA1*-linked breast cancer. *J Natl Cancer Inst* 2007;99:1683–94.
- Beleut M, Rajaram RD, Caikovski M, Ayyanan A, Germano D, Choi Y, et al. Two distinct mechanisms underlie progesterone-induced proliferation in the mammary gland. *Proc Natl Acad Sci U S A* 2010;107:2989–94.
- Asselin-Labat M-L, Vaillant F, Sheridan JM, Pal B, Wu D, Simpson ER, et al. Control of mammary stem cell function by steroid hormone signalling. *Nature* 2010;465:798–802.
- Joshi PA, Jackson HW, Birstain AG, Di Grappa MA, Mote PA, Clarke CL, et al. Progesterone induces adult mammary stem cell expansion. *Nature* 2010;465:803–7.
- Cao Y, Bonizzi G, Seagroves TN, Gretchen FR, Johnson R, Schmidt EV, et al. IKK $\alpha$  provides an essential link between RANK signaling and cyclin D1 expression during mammary gland development. *Cell* 2001;107:763–75.
- Mukherjee A, Soyak SM, Li J, Ying Y, He B, DeMayo FJ, et al. Targeting RANKL to a specific subset of murine mammary epithelial cells induces ordered branching morphogenesis and alveologenesis in the absence of progesterone receptor expression. *FASEB J* 2010;24:4408–19.

20. Ben-Neriah Y, Karin M. Inflammation meets cancer, with NF- $\kappa$ B as the matchmaker. *Nat Immunol* 2011;12:715–23.
21. O'Neill LAJ. Targeting signal transduction as a strategy to treat inflammatory diseases. *Nat Rev Drug Discov* 2006;5:549–63.
22. Häcker H, Karin M. Regulation and function of IKK and IKK-related kinases. *Sci STKE* 2006;2006:re13.
23. Solt LA, Madge LA, Orange JS, May MJ. Interleukin-1-induced NF-kappaB activation is NEMO-dependent but does not require IKKbeta. *J Biol Chem* 2007;282:8724–33.
24. Brantley DM, Yull FE, Muraoka RS, Hicks DJ, Cook CM, Kerr LD. Dynamic expression and activity of NF-kappaB during post-natal mammary gland morphogenesis. *Mech Dev* 2000;97:149–55.
25. Clarkson RW, Heeley JL, Chapman R, Aillet F, Hay RT, Wyllie A, et al. NF-kappaB inhibits apoptosis in murine mammary epithelia. *J Biol Chem* 2000;275:12737–42.
26. Fata JE, Kong YY, Li J, Sasaki T, Irie-Sasaki J, Moorehead RA, et al. The osteoclast differentiation factor osteoprotegerin-ligand is essential for mammary gland development. *Cell* 2000;103:41–50.
27. Gonzalez-Suarez E, Branstetter D, Armstrong A, Dinh H, Blumberg H, Dougall WC. RANK overexpression in transgenic mice with mouse mammary tumor virus promoter-controlled RANK increases proliferation and impairs alveolar differentiation in the mammary epithelia and disrupts lumen formation in cultured epithelial acini. *Mol Cell Biol* 2007;27:1442–54.
28. Brisken C. Progesterone signalling in breast cancer: a neglected hormone coming into the limelight. *Nat Rev Cancer* 2013;13:385–96.
29. Sovak MA, Bellas RE, Kim DW, Zanieski GJ, Rogers AE, Traish AM, et al. Aberrant nuclear factor-kappaB/Rel expression and the pathogenesis of breast cancer. *J Clin Invest* 1997;100:2952–60.
30. Nakshatri H, Bhat-Nakshatri P, Martin DA, Goulet RJ, Sledge GW. Constitutive activation of NF-kappaB during progression of breast cancer to hormone-independent growth. *Mol Cell Biol* 1997;17:3629–39.
31. Pratt MAC, Bishop TE, White D, Yasvinski G, Ménard M, Niu MY, et al. Estrogen withdrawal-induced NF-kappaB activity and bcl-3 expression in breast cancer cells: roles in growth and hormone independence. *Mol Cell Biol* 2003;23:6887–900.
32. Pratt MAC, Tibbo E, Robertson SJ, Jansson D, Hurst K, Perez-Iratxeta C, et al. The canonical NF-kappaB pathway is required for formation of luminal mammary neoplasias and is activated in the mammary progenitor population. *Oncogene* 2009;28:2710–22.
33. Huber MA, Azoitei N, Baumann B, Grünert S, Sommer A, Pehamberger H, et al. NF-kappaB is essential for epithelial-mesenchymal transition and metastasis in a model of breast cancer progression. *J Clin Invest* 2004;114:569–81.
34. Kendellen MF, Bradford JW, Lawrence CL, Clark KS, Baldwin AS. Canonical and non-canonical NF- $\kappa$ B signaling promotes breast cancer tumor-initiating cells. *Oncogene* 2014;33:1297–305.
35. Connelly L, Robinson-Benion C, Chont M, Saint-Jean L, Li H, Polosukhin VV, et al. A transgenic model reveals important roles for the NF-kappa B alternative pathway (p100/p52) in mammary development and links to tumorigenesis. *J Biol Chem* 2007;282:10028–35.
36. Wang X, Belguise K, Kersual N, Kirsch KH, Mineva ND, Galtier F, et al. Oestrogen signalling inhibits invasive phenotype by repressing RelB and its target BCL2. *Nat Cell Biol* 2007;9:470–8.
37. Fernández-Ramires R, Solé X, De Cecco L, Llorc G, Cazorla A, Bonifaci N, et al. Gene expression profiling integrated into network modelling reveals heterogeneity in the mechanisms of BRCA1 tumorigenesis. *Br J Cancer* 2009;101:1469–80.
38. Julien S, Puig I, Caretti E, Bonaventure J, Nelles L, van Roy F, et al. Activation of NF-kappaB by Akt upregulates Snail expression and induces epithelium mesenchyme transition. *Oncogene* 2007;26:7445–56.
39. Chua HL, Bhat-Nakshatri P, Clare SE, Morimiya A, Badve S, Nakshatri H. NF-kappaB represses E-cadherin expression and enhances epithelial to mesenchymal transition of mammary epithelial cells: potential involvement of ZEB-1 and ZEB-2. *Oncogene* 2007;26:711–24.
40. Pires BRB, Mencialha AL, Ferreira GM, de Souza WF, Morgado-Díaz JA, Maia AM, et al. NF-kappaB is involved in the regulation of EMT genes in breast cancer cells. *PLoS One* 2017;12:e0169622.
41. Storci G, Sansone P, Mari S, D'Uva G, Tavolari S, Guarnieri T, et al. TNFalpha up-regulates SLUG via the NF-kappaB/HIF1alpha axis, which imparts breast cancer cells with a stem cell-like phenotype. *J Cell Physiol* 2010;225:682–91.
42. Wang X, Belguise K, O'Neill CF, Sánchez-Morgan N, Romagnoli M, Eddy SF, et al. RelB NF-kappaB represses estrogen receptor alpha expression via induction of the zinc finger protein Blimp1. *Mol Cell Biol* 2009;29:3832–44.
43. Paull TT. Mechanisms of ATM activation. *Annu Rev Biochem* 2015;84:711–38.
44. Wu Z-H, Shi Y, Tibbetts RS, Miyamoto S. Molecular linkage between the kinase ATM and NF-kappaB signaling in response to genotoxic stimuli. *Science* 2006;311:1141–6.
45. Wu Z-H, Miyamoto S. Induction of a pro-apoptotic ATM-NF-kappaB pathway and its repression by ATR in response to replication stress. *EMBO J* 2008;27:1963–73.
46. Pathania S, Bade S, Le Guillou M, Burke K, Reed R, Bowman-Colin C, et al. BRCA1 haploinsufficiency for replication stress suppression in primary cells. *Nat Commun* 2014;5:5496.
47. Konishi H, Mohseni M, Tamaki A, Garay JP, Croessmann S, Karnan S, et al. Mutation of a single allele of the cancer susceptibility gene BRCA1 leads to genomic instability in human breast epithelial cells. *Proc Natl Acad Sci U S A* 2011;108:17773–8.
48. Liu S, Ginestier C, Charafé-Jauffret E, Foco H, Kleer CG, Merajver SD, et al. BRCA1 regulates human mammary stem/progenitor cell fate. *Proc Natl Acad Sci U S A* 2008;105:1680–5.
49. Lim E, Vaillant F, Wu D, Forrest NC, Pal B, Hart AH, et al. Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCA1 mutation carriers. *Nat Med* 2009;15:907–13.
50. Molyneux G, Geyer FC, Magnay F-A, McCarthy A, Kendrick H, Natrajan R, et al. BRCA1 basal-like breast cancers originate from luminal epithelial progenitors and not from basal stem cells. *Cell Stem Cell* 2010;7:403–17.
51. Bai F, Smith MD, Chan HL, Pei X-H. Germline mutation of Brca1 alters the fate of mammary luminal cells and causes luminal-to-basal mammary tumor transformation. *Oncogene* 2013;32:2715–25.
52. Proia TA, Keller PJ, Gupta PB, Klebba I, Jones AD, Sedic M, et al. Genetic predisposition directs breast cancer phenotype by dictating progenitor cell fate. *Cell Stem Cell* 2011;8:149–63.
53. Poole AJ, Li Y, Kim Y, Lin S-CJ, Lee W-H, Lee EY-HP. Prevention of Brca1-mediated mammary tumorigenesis in mice by a progesterone antagonist. *Science* 2006;314:1467–70.
54. Nolan E, Vaillant F, Branstetter D, Pal B, Giner G, Whitehead L, et al. RANK ligand as a potential target for breast cancer prevention in BRCA1-mutation carriers. *Nat Med* 2016;22:933–9.
55. Sigl V, Owusu-Boaitey K, Joshi PA, Kavirayani A, Wirnsberger G, Novatchkova M, et al. RANKL/RANK control Brca1 mutation-driven mammary tumors. *Cell Res* 2016;26:761–74.

56. Sau A, Lau R, Cabrita MA, Nolan E, Crooks PA, Visvader JE, et al. Persistent activation of NF- $\kappa$ B in *BRCA1*-deficient mammary progenitors drives aberrant proliferation and accumulation of DNA damage. *Cell Stem Cell* 2016;19:52–65.
57. Hadian K, Krappmann D. Signals from the nucleus: activation of NF- $\kappa$ B by cytosolic ATM in the DNA damage response. *Sci Signal* 2011;4:pe2.
58. Shi C, Wang Y, Guo Y, Chen Y, Liu N. Cooperative down-regulation of ribosomal protein L10 and NF- $\kappa$ B signaling pathway is responsible for the anti-proliferative effects by DMAPT in pancreatic cancer cells. *Oncotarget* 2017;8:35009–18.
59. Xu Y, Fang F, Miriyala S, Crooks PA, Oberley TD, Chaiswing L, et al. KEAP1 is a redox sensitive target that arbitrates the opposing radiosensitive effects of parthenolide in normal and cancer cells. *Cancer Res* 2013;73:4406–17.
60. Odén L, Akbari M, Zaman T, Singer CF, Sun P, Narod SA, et al. Plasma osteoprotegerin and breast cancer risk in *BRCA1* and *BRCA2* mutation carriers. *Oncotarget* 2016;7:86687–94.
61. Vik A, Brodin EE, Mathiesen EB, Brox J, Jørgensen L, Njølstad I, et al. Serum osteoprotegerin and future risk of cancer and cancer-related mortality in the general population: the Tromsø study. *Eur J Epidemiol* 2015;30:219–30.
62. Widschwendter M, Burnell M, Fraser L, Rosenthal AN, Philpott S, Reisel D, et al. Osteoprotegerin (OPG), the endogenous inhibitor of receptor activator of NF- $\kappa$ B ligand (RANKL), is dysregulated in *BRCA* mutation carriers. *EBioMedicine* 2015;2:1331–9.
63. Widschwendter M, Rosenthal AN, Philpott S, Rizzuto I, Fraser L, Hayward J, et al. The sex hormone system in carriers of *BRCA1/2* mutations: a case-control study. *Lancet Oncol* 2013;14:1226–32.
64. Fortner RT, Sarink D, Schock H, Johnson T, Tjønneland A, Olsen A, et al. Osteoprotegerin and breast cancer risk by hormone receptor subtype: a nested case-control study in the EPIC cohort. *BMC Med* 2017;15:26.
65. Kotsopoulos J, Huzarski T, Gronwald J, Singer CF, Moller P, Lynch HT, et al. Bilateral oophorectomy and breast cancer risk in *BRCA1* and *BRCA2* mutation carriers. *J Natl Cancer Inst* 2017;109:pjii:djw177.
66. Foulkes WD, Metcalfe K, Sun P, Hanna WM, Lynch HT, Ghadirian P, et al. Estrogen receptor status in *BRCA1*- and *BRCA2*-related breast cancer: the influence of age, grade, and histological type. *Clin Cancer Res* 2004;10:2029–34.
67. Tung N, Wang Y, Collins LC, Kaplan J, Li H, Gelman R, et al. Estrogen receptor positive breast cancers in *BRCA1* mutation carriers: clinical risk factors and pathologic features. *Breast Cancer Res* 2010;12:R12.
68. Shoker BS, Jarvis C, Clarke RB, Anderson E, Hewlett J, Davies MP, et al. Estrogen receptor-positive proliferating cells in the normal and precancerous breast. *Am J Pathol* 1999;155:1811–5.
69. Chand AL, kConFab, Simpson ER, Clyne CD. Aromatase expression is increased in *BRCA1* mutation carriers. *BMC Cancer* 2009;9:148.
70. Hu Y, Ghosh S, Amleh A, Yue W, Lu Y, Katz A, et al. Modulation of aromatase expression by *BRCA1*: a possible link to tissue-specific tumor suppression. *Oncogene* 2005;24:8343–8.
71. Cleland WH, Mendelson CR, Simpson ER. Effects of aging and obesity on aromatase activity of human adipose cells. *J Clin Endocrinol Metab* 1985;60:174–7.
72. Fan S, Ma YX, Wang C, Yuan RQ, Meng Q, Wang JA, et al. Role of direct interaction in *BRCA1* inhibition of estrogen receptor activity. *Oncogene* 2001;20:77–87.
73. Yamaguchi Y, Takei H, Suemasu K, Kobayashi Y, Kurosumi M, Harada N, et al. Tumor-stromal interaction through the estrogen-signaling pathway in human breast cancer. *Cancer Res* 2005;65:4653–62.
74. Lawson JS, Field AS, Champion S, Tran D, Ishikura H, Trichopoulos D. Low oestrogen receptor alpha expression in normal breast tissue underlies low breast cancer incidence in Japan. *Lancet* 1999;354:1787–8.
75. Shyamala G, Chou Y-C, Louie SG, Guzman RC, Smith GH, Nandi S. Cellular expression of estrogen and progesterone receptors in mammary glands: regulation by hormones, development and aging. *J Steroid Biochem Mol Biol* 2002;80:137–48.
76. Duyao MP, Buckler AJ, Sonenshein GE. Interaction of an NF- $\kappa$ B-like factor with a site upstream of the c-myc promoter. *Proc Natl Acad Sci U S A* 1990;87:4727–31.
77. Blakely CM, Sintasath L, D'Cruz CM, Hahn KT, Dugan KD, Belka GK, et al. Developmental stage determines the effects of MYC in the mammary epithelium. *Development* 2005;132:1147–60.
78. Chen Y, Xu J, Borowicz S, Collins C, Huo D, Olopade OI. c-Myc activates *BRCA1* gene expression through distal promoter elements in breast cancer cells. *BMC Cancer* 2011;11:246.
79. Wang Q, Zhang H, Kajino K, Greene MI. *BRCA1* binds c-Myc and inhibits its transcriptional and transforming activity in cells. *Oncogene* 1998;17:1939–48.
80. Gorski JJ, James CR, Quinn JE, Stewart GE, Staunton KC, Buckley NE, et al. *BRCA1* transcriptionally regulates genes associated with the basal-like phenotype in breast cancer. *Breast Cancer Res Treat* 2010;122:721–31.
81. Xu J, Chen Y, Olopade OI. MYC and breast cancer. *Genes Cancer* 2010;1:629–40.
82. Casimiro MC, Wang C, Li Z, Di Sante G, Willmart NE, Addya S, et al. Cyclin D1 determines estrogen signaling in the mammary gland *in vivo*. *Mol Endocrinol* 2013;27:1415–28.
83. Sicinski P, Donaher JL, Parker SB, Li T, Fazeli A, Gardner H, et al. Cyclin D1 provides a link between development and oncogenesis in the retina and breast. *Cell* 1995;82:621–30.
84. Wang C, Fan S, Li Z, Fu M, Rao M, Ma Y, et al. Cyclin D1 antagonizes *BRCA1* repression of estrogen receptor alpha activity. *Cancer Res* 2005;65:6557–67.
85. Colombo M, Giarola M, Mariani L, Ripamonti CB, De Benedetti V, Sardella M, et al. Cyclin D1 expression analysis in familial breast cancers may discriminate BRCAX from *BRCA2*-linked cases. *Mod Pathol* 2008;21:1262–70.
86. Yan M, kConFab Investigators, Fox SB. Does cyclin D1 discriminate between *BRCA2* and BRCAX breast cancers? *Histopathology* 2009;55:625–6.
87. Iliopoulos D, Hirsch HA, Struhl K. An epigenetic switch involving NF- $\kappa$ B, Lin28, Let-7 MicroRNA, and IL6 links inflammation to cell transformation. *Cell* 2009;139:693–706.
88. Bachelot T, Ray-Coquard I, Menetrier-Caux C, Rastkha M, Duc A, Blay J-Y. Prognostic value of serum levels of interleukin 6 and of serum and plasma levels of vascular endothelial growth factor in hormone-refractory metastatic breast cancer patients. *Br J Cancer* 2003;88:1721–6.
89. Knüpfer H, Preiss R. Significance of interleukin-6 (IL-6) in breast cancer (review). *Breast Cancer Res Treat* 2007;102:129–35.
90. Rokavec M, Wu W, Luo J-L. IL6-mediated suppression of miR-200c directs constitutive activation of inflammatory signaling circuit driving transformation and tumorigenesis. *Mol Cell* 2012;45:777–89.
91. Sansone P, Storci G, Tavolari S, Guarnieri T, Giovannini C, Taffurelli M, et al. IL-6 triggers malignant features in mammospheres from human ductal breast carcinoma and normal mammary gland. *J Clin Invest* 2007;117:3988–4002.

Sau et al.

92. Iqbal J, Ragone A, Lubinski J, Lynch HT, Moller P, Ghadirian P, et al. The incidence of pancreatic cancer in BRCA1 and BRCA2 mutation carriers. *Br J Cancer* 2012;107:2005–9.
93. Phelan CM, Iqbal J, Lynch HT, Lubinski J, Gronwald J, Moller P, et al. Incidence of colorectal cancer in BRCA1 and BRCA2 mutation carriers: results from a follow-up study. *Br J Cancer* 2014;110:530–4.
94. Thyss R, Virolle V, Imbert V, Peyron J-F, Aberdam D, Virolle T. NF-kappaB/Egr-1/Gadd45 are sequentially activated upon UVB irradiation to mediate epidermal cell death. *EMBO J* 2005;24:128–37.
95. Baxter FO, Came PJ, Abell K, Kedjouar B, Huth M, Rajewsky K, et al. IKKbeta/2 induces TWEAK and apoptosis in mammary epithelial cells. *Development* 2006;133:3485–94.
96. Narazaki M, Tanaka T, Kishimoto T. The role and therapeutic targeting of IL-6 in rheumatoid arthritis. *Expert Rev Clin Immunol* 2017;13:535–51.
97. Shuen AY, Foulkes WD. Inherited mutations in breast cancer genes—risk and response. *J Mammary Gland Biol Neoplasia* 2011;16:3–15.
98. Mavaddat N, Peock S, Frost D, Ellis S, Platte R, Fineberg E, et al. Cancer risks for BRCA1 and BRCA2 mutation carriers: results from prospective analysis of EMBRACE. *J Natl Cancer Inst* 2013;105:812–22.
99. Evans MK, Longo DL. PALB2 mutations and breast-cancer risk. *N Engl J Med* 2014;371:566–8.
100. Tischkowitz M, Xia B. PALB2/FANCN: recombining cancer and Fanconi anemia. *Cancer Res* 2010;70:7353–9.
101. Larsen MJ, Kruse TA, Tan Q, Lænkholm A-V, Bak M, Lykkesfeldt AE, et al. Classifications within molecular subtypes enables identification of BRCA1/BRCA2 mutation carriers by RNA tumor profiling. *PLoS One* 2013;8:e64268.
102. Wang H, Bierie B, Li AG, Pathania S, Toomire K, Dimitrov SD, et al. BRCA1/FANCD2/BRG1-driven DNA repair stabilizes the differentiation state of human mammary epithelial cells. *Mol Cell* 2016;63:277–92.
103. Ades F, Zardavas D, Bozovic-Spasojevic I, Pugliano L, Fumagalli D, de Azambuja E, et al. Luminal B breast cancer: molecular characterization, clinical management, and future perspectives. *J Clin Oncol* 2014;32:2794–803.
104. Cvorovic A, Tzagarakis-Foster C, Tatomer D, Paruthiyil S, Fox MS, Leitman DC. Distinct roles of unliganded and liganded estrogen receptors in transcriptional repression. *Mol Cell* 2006;21:555–64.
105. Ghisletti S, Meda C, Maggi A, Vegeto E. 17beta-estradiol inhibits inflammatory gene expression by controlling NF-kappaB intracellular localization. *Mol Cell Biol* 2005;25:2957–68.
106. Gionet N, Jansson D, Mader S, Pratt MAC. NF-kappaB and estrogen receptor alpha interactions: differential function in estrogen receptor-negative and -positive hormone-independent breast cancer cells. *J Cell Biochem* 2009;107:448–59.
107. Biswas DK, Shi Q, Baily S, Strickland I, Ghosh S, Pardee AB, et al. NF-kappa B activation in human breast cancer specimens and its role in cell proliferation and apoptosis. *Proc Natl Acad Sci U S A* 2004;101:10137–42.
108. Franco HL, Nagari A, Kraus WL. TNF $\alpha$  signaling exposes latent estrogen receptor binding sites to alter the breast cancer cell transcriptome. *Mol Cell* 2015;58:21–34.
109. Adamson AD, Friedrichsen S, Semprini S, Harper CV, Mullins JJ, White MRH, et al. Human prolactin gene promoter regulation by estrogen: convergence with tumor necrosis factor-alpha signaling. *Endocrinology* 2008;149:687–94.
110. Rubio MF, Werbajh S, Cafferata EGA, Quaglino A, Coló GP, Nojek IM, et al. TNF-alpha enhances estrogen-induced cell proliferation of estrogen-dependent breast tumor cells through a complex containing nuclear factor-kappa B. *Oncogene* 2006;25:1367–77.
111. Frasar J, Weaver A, Pradhan M, Dai Y, Miller LD, Lin C-Y, et al. Positive cross-talk between estrogen receptor and NF-kappaB in breast cancer. *Cancer Res* 2009;69:8918–25.
112. Park K-J, Krishnan V, O'Malley BW, Yamamoto Y, Gaynor RB. Formation of an IKKalpha-dependent transcription complex is required for estrogen receptor-mediated gene activation. *Mol Cell* 2005;18:71–82.
113. Sy SMH, Huen MSY, Chen J. PALB2 is an integral component of the BRCA complex required for homologous recombination repair. *Proc Natl Acad Sci U S A* 2009;106:7155–60.
114. Zhang F, Ma J, Wu J, Ye L, Cai H, Xia B, et al. PALB2 links BRCA1 and BRCA2 in the DNA-damage response. *Curr Biol* 2009;19:524–9.
115. Oliver AW, Swift S, Lord CJ, Ashworth A, Pearl LH. Structural basis for recruitment of BRCA2 by PALB2. *EMBO Rep* 2009;10:990–6.
116. Antoniou AC, Casadei S, Heikkinen T, Barrowdale D, Pykäs K, Roberts J, et al. Breast-cancer risk in families with mutations in PALB2. *N Engl J Med* 2014;371:497–506.
117. Heikkinen T, Kärkkäinen H, Aaltonen K, Milne RL, Heikkilä P, Aittomäki K, et al. The breast cancer susceptibility mutation PALB2 1592delT is associated with an aggressive tumor phenotype. *Clin Cancer Res* 2009;15:3214–22.
118. Foo TK, Tischkowitz M, Simhadri S, Boshari T, Zayed N, Burke KA, et al. Compromised BRCA1-PALB2 interaction is associated with breast cancer risk. *Oncogene* 2017;36:4161–70.

# Cancer Prevention Research

## NF- $\kappa$ B at the Crossroads of Normal Mammary Gland Biology and the Pathogenesis and Prevention of *BRCA1*-Mutated Breast Cancer

Andrea Sau, Miguel A. Cabrita and M.A. Christine Pratt

*Cancer Prev Res* 2018;11:69-80. Published OnlineFirst November 3, 2017.

**Updated version** Access the most recent version of this article at:  
doi:[10.1158/1940-6207.CAPR-17-0225](https://doi.org/10.1158/1940-6207.CAPR-17-0225)

**Cited articles** This article cites 118 articles, 36 of which you can access for free at:  
<http://cancerpreventionresearch.aacrjournals.org/content/11/2/69.full#ref-list-1>

**E-mail alerts** [Sign up to receive free email-alerts](#) related to this article or journal.

**Reprints and Subscriptions** To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at [pubs@aacr.org](mailto:pubs@aacr.org).

**Permissions** To request permission to re-use all or part of this article, use this link <http://cancerpreventionresearch.aacrjournals.org/content/11/2/69>. Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.